Phase I Study of PDR001 in Patients With Advanced Malignancies.
Status:
Completed
Trial end date:
2017-09-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety, tolerability, Pharmacokinetics (PK),
and antitumor activity of PDR001 administered intravenous (i.v.) as a single agent to
Japanese patients.